Alas, porphyria

For over two decades, treatment of acute porphyrias has relied on hemin infusions that restore heme levels, but the therapy is slow to work, has side effects and is expensive. Now, a team led by Alnylam Pharmaceuticals Inc. has created an siRNA therapeutic that reduces disease symptoms in mice.1

However, to really improve patient care, the company will also need a strategy to raise awareness and combat misdiagnosis of these rare disorders.

Alnylam is completing IND-enabling toxicity studies. The company expects to submit an IND in 2014 and start clinical trials in 2015.

Acute hepatic porphyrias are orphan diseases caused by enzyme deficiencies that disrupt heme biosynthesis and ultimately result in misregulation of aminolevulinate synthase-1 (ALAS-1), the first enzyme in the heme biosynthetic pathway. These inherited disorders are characterized by life-threatening acute attacks that include severe abdominal pain, muscle weakness, seizures and paralysis.

According to Karl Anderson,

Read the full 1432 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE